Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche

Stem Cell Reports. 2024 Feb 13;19(2):224-238. doi: 10.1016/j.stemcr.2023.12.011. Epub 2024 Jan 25.

Abstract

The myeloproliferative disease polycythemia vera (PV) driven by the JAK2 V617F mutation can transform into myelofibrosis (post-PV-MF). It remains an open question how JAK2 V617F in hematopoietic stem cells induces MF. Megakaryocytes are major players in murine PV models but are difficult to study in the human setting. We generated induced pluripotent stem cells (iPSCs) from JAK2 V617F PV patients and differentiated them into megakaryocytes. In differentiation assays, JAK2 V617F iPSCs recapitulated the pathognomonic skewed megakaryocytic and erythroid differentiation. JAK2 V617F iPSCs had a TPO-independent and increased propensity to differentiate into megakaryocytes. RNA sequencing of JAK2 V617F iPSC-derived megakaryocytes reflected a proinflammatory, profibrotic phenotype and decreased ribosome biogenesis. In three-dimensional (3D) coculture, JAK2 V617F megakaryocytes induced a profibrotic phenotype through direct cell contact, which was reversed by the JAK2 inhibitor ruxolitinib. The 3D coculture system opens the perspective for further disease modeling and drug discovery.

MeSH terms

  • Animals
  • Bone Marrow / pathology
  • Fibrosis
  • Humans
  • Induced Pluripotent Stem Cells*
  • Janus Kinase 2 / genetics
  • Megakaryocytes
  • Mice
  • Mutation
  • Phenotype
  • Polycythemia Vera* / genetics
  • Polycythemia Vera* / pathology

Substances

  • Janus Kinase 2
  • JAK2 protein, human